Gabelli & Co Investment Advisers’s Vaxart VXRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-18,843
Closed -$54K 182
2018
Q3
$54K Hold
18,843
0.01% 176
2018
Q2
$57K Hold
18,843
0.01% 158
2018
Q1
$100K Sell
18,843
-1,564
-8% -$10.1K 0.01% 153
2017
Q4
$127K Hold
20,407
0.02% 156
2017
Q3
$154K Hold
20,407
0.02% 157
2017
Q2
$150K Hold
20,407
0.02% 160
2017
Q1
$146K Hold
20,407
0.02% 148
2016
Q4
$276K Hold
20,407
0.03% 121
2016
Q3
$431K Hold
20,407
0.05% 115
2016
Q2
$314K Sell
20,407
-45
-0.2% -$748 0.04% 135
2016
Q1
$337K Buy
20,452
+618
+3% +$11K 0.04% 127
2015
Q4
$423K Sell
19,834
-6,785
-25% -$149K 0.05% 123
2015
Q3
$580K Hold
26,619
0.08% 103
2015
Q2
$606K Hold
26,619
0.09% 104
2015
Q1
$673K Hold
26,619
0.11% 82
2014
Q4
$656K Sell
26,619
-7,754
-23% -$199K 0.09% 89
2014
Q3
$934K Buy
34,373
+1,585
+5% +$45.5K 0.15% 96
2014
Q2
$1.03M Buy
32,788
+4,418
+16% +$185K 0.22% 73
2014
Q1
$1.91M Sell
28,370
-6,816
-19% -$422K 0.52% 45
2013
Q4
$1.62M Sell
35,186
-876
-2% -$38.5K 0.59% 43
2013
Q3
$1.66M Hold
36,062
0.36% 55
2013
Q2
$1.37M Buy
+36,062
New +$1.5M 0.36% 48

Other funds holding VXRT

Gabelli & Co Investment Advisers's VXRT Position: Q4 2018 in Review

Gabelli & Co Investment Advisers sold out of Vaxart (VXRT) in Q4 2018, closing a stake of 18,843 shares — an estimated $54K sold.

Gabelli & Co Investment Advisers first reported a position in VXRT in Q2 2013 and held it in 22 quarters. The position peaked at $1.91M in Q1 2014. 21 funds tracked by Wall St. Rank hold VXRT as of Q4 2018.

  • Gabelli & Co Investment Advisers reported no remaining Vaxart position as of Q4 2018 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 18,843 Vaxart shares in Q4 2018, an estimated $54K.
  • Gabelli & Co Investment Advisers first reported a position in Vaxart in Q2 2013 and held it in 22 quarters.
  • Gabelli & Co Investment Advisers's Vaxart position peaked at $1.91M in Q1 2014.
  • 21 funds tracked by Wall St. Rank held Vaxart as of Q4 2018.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.